C4 Therapeutics (CCCC)
(Delayed Data from NSDQ)
$5.38 USD
+0.04 (0.75%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $5.23 -0.15 (-2.79%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
CCCC 5.38 +0.04(0.75%)
Will CCCC be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CCCC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CCCC
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
Community Health Systems (CYH) Reports Q2 Loss, Tops Revenue Estimates
CCCC: What are Zacks experts saying now?
Zacks Private Portfolio Services
C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?
C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates
Other News for CCCC
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Stifel Nicolaus Keeps Their Buy Rating on C4 Therapeutics (CCCC)
Cautious Hold Rating on C4 Therapeutics Amid Modest Efficacy and Pending Data
Hold Rating on C4 Therapeutics Amid Early-Stage Drug Development and Market Caution
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024